tiprankstipranks
Trending News
More News >

Syntara Limited Reports Positive Interim Data for SNT-5505 in Myelofibrosis Trial

Story Highlights
Syntara Limited Reports Positive Interim Data for SNT-5505 in Myelofibrosis Trial

Don’t Miss TipRanks’ Half-Year Sale

Pharmaxis Ltd ( (AU:SNT) ) just unveiled an announcement.

Syntara Limited, a clinical-stage drug development company, has announced positive interim data from its Phase 2 clinical trial of SNT-5505 in combination with ruxolitinib for treating myelofibrosis. The results, to be presented at the European Hematology Association Conference, show significant improvements in patient symptoms and spleen volume, highlighting SNT-5505’s potential to change long-term outcomes for myelofibrosis patients. The drug has demonstrated a good safety profile with no serious adverse events, and the company plans to engage with the FDA for further study designs.

The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.25 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.

More about Pharmaxis Ltd

Average Trading Volume: 8,136,081

Technical Sentiment Signal: Buy

Current Market Cap: A$112.1M

For a thorough assessment of SNT stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1